Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke
Status:
Completed
Trial end date:
2018-02-01
Target enrollment:
Participant gender:
Summary
Patients presenting to the emergency department with acute ischemic stroke, who are are
eligible for standard intravenous tPA therapy within 4.5 hours of stroke onset will be
assessed for major vessel occlusion to determine their eligibility for randomization into the
trial. If the patient gives informed consent they will be randomised 50:50 using central
computerised allocation to intravenous alteplase or tenecteplase before all participants
undergo intra-arterial clot retrieval. The trial is prospective, randomised, open-label,
blinded endpoint (PROBE) design.
Phase:
Phase 2
Details
Lead Sponsor:
Neuroscience Trials Australia
Collaborator:
The Florey Institute of Neuroscience and Mental Health